JPWO2020033019A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020033019A5
JPWO2020033019A5 JP2021509963A JP2021509963A JPWO2020033019A5 JP WO2020033019 A5 JPWO2020033019 A5 JP WO2020033019A5 JP 2021509963 A JP2021509963 A JP 2021509963A JP 2021509963 A JP2021509963 A JP 2021509963A JP WO2020033019 A5 JPWO2020033019 A5 JP WO2020033019A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cancer
subject
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021509963A
Other languages
English (en)
Other versions
JP2021522345A (ja
JP7115671B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/029192 external-priority patent/WO2020033019A2/en
Publication of JP2021522345A publication Critical patent/JP2021522345A/ja
Publication of JPWO2020033019A5 publication Critical patent/JPWO2020033019A5/ja
Application granted granted Critical
Publication of JP7115671B2 publication Critical patent/JP7115671B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (9)

  1. 式IIIの構造を有する化合物又はその塩と、及び1つ又は複数の薬学的に許容できる賦形剤又は添加剤と、を含む、医薬組成物。
    Figure 2020033019000001

    [式中、X及びYは、水素、塩素、フッ素、臭素及びヨウ素から独立的に選択される。]
  2. X及びYがフッ素である、請求項1に記載の医薬組成物。
  3. 経口又は非経口の投与用に設計されるか又は製剤化されている、請求項1又は2に記載の医薬組成物。
  4. MCT4を発現するがんを治療するために、それを必要とする対象に投与するための使用のための、請求項1~3のいずれか一項に記載の医薬組成物。
  5. 治療有効量のメトホルミンとともに前記対象に投与するための使用のための、請求項4に記載の医薬組成物。
  6. 前記対象がヒトである、請求項4又は5に記載の医薬組成物。
  7. 前記がんが、癌腫、肉腫、神経新生物、リンパ腫、骨髄腫、白血病、黒色腫、中皮腫、固形がん又は軟部組織腫瘍である、請求項4~6のいずれか一項に記載の医薬組成物。
  8. 前記がんが乳癌である、請求項4~7のいずれか一項に記載の医薬組成物。
  9. 請求項1~のいずれか一項に記載の組成物を備える、キット。
JP2021509963A 2018-04-25 2019-04-25 新規なmct4阻害剤及びその使用 Active JP7115671B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662637P 2018-04-25 2018-04-25
US62/662,637 2018-04-25
PCT/US2019/029192 WO2020033019A2 (en) 2018-04-25 2019-04-25 Novel mct4 inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2021522345A JP2021522345A (ja) 2021-08-30
JPWO2020033019A5 true JPWO2020033019A5 (ja) 2022-04-28
JP7115671B2 JP7115671B2 (ja) 2022-08-09

Family

ID=68532786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509963A Active JP7115671B2 (ja) 2018-04-25 2019-04-25 新規なmct4阻害剤及びその使用

Country Status (7)

Country Link
US (1) US10919878B2 (ja)
EP (1) EP3784650B1 (ja)
JP (1) JP7115671B2 (ja)
CN (1) CN112888673B (ja)
AU (1) AU2019317518B2 (ja)
CA (1) CA3098189A1 (ja)
WO (1) WO2020033019A2 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220075344A (ko) * 2019-09-05 2022-06-08 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 미토콘드리아 기능을 변형시키는 방법 및 화합물
WO2021249969A1 (en) * 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
WO2022243574A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use
WO2022243573A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226438A (ja) * 1968-12-03 1971-03-31
GB0327734D0 (en) * 2003-11-28 2003-12-31 Novartis Ag Organic compounds
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
WO2010089580A1 (en) * 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
CN102731413A (zh) * 2011-04-15 2012-10-17 上海医药工业研究院 一种脲类化合物、其制备方法、其中间体及其应用
CN105263484B (zh) * 2013-05-24 2018-08-03 株式会社加龄.营养研究所 包含二甲双胍和二氢槲皮素的药物组合及其用于治疗癌症的用途
WO2016081464A1 (en) * 2014-11-17 2016-05-26 Nirogyone Therapeutics, Inc. Monocarboxylate transport modulators and uses thereof
WO2016118822A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Chromenone inhibitors of monocarboxylate transporters
EP3247361A4 (en) * 2015-01-22 2018-08-15 The Scripps Research Institute Pteridine dione monocarboxylate transporter inhibitors
JP6944442B2 (ja) * 2015-06-12 2021-10-06 ベットーレ リミテッド ライアビリティー カンパニーVettore, Llc 疾患を治療するためのmct4阻害剤
CN108368060B (zh) * 2017-12-21 2020-09-15 中国科学院合肥物质科学研究院 一类嘧啶类衍生物激酶抑制剂

Similar Documents

Publication Publication Date Title
JP2008521928A5 (ja)
JP2019503365A5 (ja)
RU2016141934A (ru) Ингибиторы циклин-зависимой киназы 7 (cdk7)
JP2021063088A5 (ja)
JP2016518437A5 (ja)
JP2012082234A5 (ja)
JP2020531463A5 (ja)
JPWO2020033019A5 (ja)
US10561647B2 (en) Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof
JPWO2020131674A5 (ja)
JP2017039714A5 (ja)
JP2018140987A5 (ja)
JP2021503451A5 (ja)
JP2019517474A5 (ja)
JP2013523867A5 (ja)
JP2008546777A5 (ja)
JP2020506886A5 (ja)
MX2023004085A (es) Metodos para el tratamiento del cáncer.
JPWO2019232257A5 (ja)
JP2004528311A5 (ja)
JPWO2021087136A5 (ja)
JPWO2020103859A5 (ja)
JP2009518393A5 (ja)
JP2020533399A5 (ja)
JP2020517731A5 (ja)